Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS1-144 in Participants with Hepatic Impairment and Healthy Female
NCT07491289Phase 1Not yet recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GS1-144, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Maximum concentration, Area under the curve from time 0 to the last time with quantifiable concentration and 4 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
GS1-144
Beyond the preview
Go deeper on NCT07491289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07491289.